European Respiratory Society Annual Congress 2012 Abstract Number: 4883 Publication Number: P2379 Abstract Group: 5.3. Allergy and Immunology Keyword 1: Asthma - management Keyword 2: Allergy Keyword 3: Epidemiology Title: Gender medicine and different prevalence in asthma by reports on anti-IgE (omalizumab) treatments Prof. Dr Vincenzo 30541 Patella
[email protected] MD 1, Dr. Carmine 30542 Oricchio
[email protected] MD 2, Dr. Giovanni 30543 Florio
[email protected] MD 1 and Dr. Ada 30595 Giuliano
[email protected] 3. 1 Division of Clinical Immunology and Allergy, General Hospital, ASL Salerno, Agropoli, Salerno, Italy, I-84043 ; 2 Division of Transfusion Medicine, General Hospital, ASL Salerno, Agropoli, Salerno, Italy, I-84043 and 3 Public Health Hygiene, ASL Salerno, Vallo della Lucania, Salerno, Italy, I-84078 . Body: Background: Generally, pathogenesis and prevalence of bronchial asthma indicates that age and sex are the major risk factors. Detailed physiological mechanisms of the changing sex ratio are not fully known. We investigated the influence of gender in anti-IgE treated asthmatics. Methods: We pooled data from ten published studies from 1999 with more of our data of severe persistent asthmatics treated with omalizumab (anti-IgE) monoclonal antibody. Static analysis was used to find gender risk factors as the ratio of treatment effect (omalizumab : control) on standardized exacerbation rate per year. Results: The studies included 3270 omalizumab treated patients, whose had severe persistent asthma according to